Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection
A Randomized, Double-Blind Trial Comparing Linezolid To Vancomycin In The Empiric Treatment Of Febrile Neutropenic Oncology Patients With Suspected Gram-Positive Infections
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
- Pfizer Investigational Site
-
-
-
-
-
Buenos Aires, Argentina, 1094
- Pfizer Investigational Site
-
Cordoba, Argentina, 5000
- Pfizer Investigational Site
-
Mendoza, Argentina, 5500
- Pfizer Investigational Site
-
-
-
-
-
São Paulo, Brazil, 04024-002
- Pfizer Investigational Site
-
São Paulo, Brazil, 05651-901
- Pfizer Investigational Site
-
-
RS
-
Porto Alegre, RS, Brazil, 90610-000
- Pfizer Investigational Site
-
Porto Alegre, RS, Brazil, 90020-090
- Pfizer Investigational Site
-
-
SP
-
Sao Paulo, SP, Brazil, 01509-900
- Pfizer Investigational Site
-
São Paulo, SP, Brazil, 01409-902
- Pfizer Investigational Site
-
-
-
-
-
Santiago, Chile
- Pfizer Investigational Site
-
-
-
-
-
Medellin, Colombia
- Pfizer Investigational Site
-
-
Bogota. DC
-
Bogota, Bogota. DC, Colombia, NAP
- Pfizer Investigational Site
-
Bogota, Bogota. DC, Colombia
- Pfizer Investigational Site
-
-
-
-
-
Helsinki, Finland, FIN-00029 HYKS
- Pfizer Investigational Site
-
-
-
-
-
Mexico D.f., Mexico, C.P. 02990
- Pfizer Investigational Site
-
-
Jalisco
-
Zapopan, Jalisco, Mexico, 45173
- Pfizer Investigational Site
-
-
Nuevo Leon
-
Monterrey, Nuevo Leon, Mexico, C.P. 64000
- Pfizer Investigational Site
-
-
-
-
-
Karachi, Pakistan, 74800
- Pfizer Investigational Site
-
-
Punjab
-
Lahore, Punjab, Pakistan
- Pfizer Investigational Site
-
-
-
-
-
Lima, Peru, 13
- Pfizer Investigational Site
-
Lima, Peru, 34
- Pfizer Investigational Site
-
-
-
-
California
-
Los Angeles, California, United States, 90033
- Pfizer Investigational Site
-
-
Illinois
-
Springfield, Illinois, United States, 62703
- Pfizer Investigational Site
-
Springfield, Illinois, United States, 62701-1014
- Pfizer Investigational Site
-
Springfield, Illinois, United States, 62769
- Pfizer Investigational Site
-
Springfield, Illinois, United States, 62781
- Pfizer Investigational Site
-
-
New York
-
Bronx, New York, United States, 10461
- Pfizer Investigational Site
-
Bronx, New York, United States, 10467
- Pfizer Investigational Site
-
-
Texas
-
Houston, Texas, United States, 77030
- Pfizer Investigational Site
-
-
Virginia
-
Richmond, Virginia, United States, 23229
- Pfizer Investigational Site
-
Richmond, Virginia, United States, 23249
- Pfizer Investigational Site
-
Richmond, Virginia, United States, 23294
- Pfizer Investigational Site
-
Richmond, Virginia, United States, 23226
- Pfizer Investigational Site
-
Richmond, Virginia, United States, 23294-4367
- Pfizer Investigational Site
-
-
Washington
-
Federal Way, Washington, United States, 98003
- Pfizer Investigational Site
-
Lakewood, Washington, United States, 98499
- Pfizer Investigational Site
-
Tacoma, Washington, United States, 98405
- Pfizer Investigational Site
-
-
-
-
-
Caracas, Venezuela, 1020
- Pfizer Investigational Site
-
-
Distrito Federal
-
Caracas, Distrito Federal, Venezuela, 1041
- Pfizer Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients must have neutropenia (ANC less than 500) with fever (oral temp 38.3 C).
Patients must have a cancer with recent chemotherapy and risks factors for gram positive infections.
Exclusion Criteria:
Patients with fever due to known causes. Patients with HIV. Patients with recent bone marrow transplant. Patients with an infected indwelling catheter that cannot be removed. Patients who have received more than one day of another antibiotic before entering the trial.
Patients with endocarditis, osteomyelitis, meningitis, CNS infections.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: B.
|
1gm every 12 hours.
The dose of vancomycin intravenously may be adjusted for renal function, but the patient must be able to receive a 300 mL volume of intravenous fluid at the assigned dosing times of every 12 hours.
|
|
Experimental: A.
Patients will be stratified according to the use of prophylactic antibiotics.
Both groups may receive open-label gram-negative coverage with either ceftazidime, aztreonam, and/or aminoglycosides (gentamicin, tobramycin, amikacin).
Subjects will receive study medication intravenously every 12 hours for 7 to 28 days.
|
600mg every 12 hours
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Clinical efficacy of linezolid when administered intravenously as compared to intravenously administered vancomycin in the empiric treatment of oncology patients with febrile neutropenia with suspected gram-positive infections.
Time Frame: 7-28 days
|
7-28 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Microbiologic outcome
Time Frame: 7-28 days
|
7-28 days
|
|
Pathogen eradication (eradication rates of individual pathogens)
Time Frame: 7-28 days
|
7-28 days
|
|
Defervescence (defined as Tmax orally or rectally)
Time Frame: 7-28 days
|
7-28 days
|
|
Time to defervescence
Time Frame: 7-28 days
|
7-28 days
|
|
Resolution of neutropenia (return of ANC to >500 cells/mm3)
Time Frame: 7-28 days
|
7-28 days
|
|
Time to resolution of neutropenia
Time Frame: 7-28 days
|
7-28 days
|
|
Mortality rate (survival at 7 days after the end of therapy)
Time Frame: 7-28 days
|
7-28 days
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Wounds and Injuries
- Hematologic Diseases
- Agranulocytosis
- Leukopenia
- Leukocyte Disorders
- Body Temperature Changes
- Heat Stress Disorders
- Neutropenia
- Hyperthermia
- Fever
- Febrile Neutropenia
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Anti-Bacterial Agents
- Protein Synthesis Inhibitors
- Vancomycin
- Linezolid
Other Study ID Numbers
Other Study ID Numbers
- M12600079
- A5951059
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.